Nexviadyme (Avalglucosidase Alfa)

Avalglucosidase alfa is a recombinant form of human acid α‑glucosidase. After intravenous infusion, it is taken up by cells via the mannose‑6‑phosphate receptor and delivered to lysosomes, where it catalyses the breakdown of accumulated glycogen into glucose, thereby restoring normal cellular function.

The dosing regimen for Nexviadyme is individualized. A qualified prescriber determines the appropriate dose, infusion rate, and treatment schedule based on the patient’s age, weight, disease severity and clinical response. Exact dosing instructions are provided in the prescribing information and should not be altered without medical guidance.

Safety data for Nexviadyme in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Women who are breastfeeding should discuss potential exposure with their healthcare provider, as it is unclear whether the drug is excreted in breast milk.

To order Nexviadyme, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

The primary alternative for Pompe disease is alglucosidase alfa (Myozyme/Lumizyme). Both are recombinant acid α‑glucosidases, but Nexviadyme has been engineered for higher mannose‑6‑phosphate receptor affinity, potentially allowing more efficient cellular uptake. Clinical outcomes and safety profiles are comparable, though individual patient response may vary.

Nexviadyme must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to infusion, the product may be gently mixed if required, and any unused portion should be discarded according to local regulations.

Nexviadyme is administered by intravenous infusion in a clinical setting. The infusion is typically started at a low rate and gradually increased as tolerated, following the prescribing information. Trained healthcare professionals monitor the patient for infusion‑related reactions throughout the procedure.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, cardiac arrhythmias, pulmonary hypertension, and the development of neutralising antibodies that may diminish therapeutic effect. Patients should be observed closely during and after infusion, and any signs of severe reaction require immediate medical intervention.

Nexviadyme is contraindicated in individuals with known hypersensitivity to avalglucosidase alfa or any of its excipients. Patients with uncontrolled severe cardiac disease, active infections, or those who have experienced severe infusion reactions to similar enzyme therapies should avoid use unless a specialist determines that benefits outweigh risks.